Autor: |
Romano ER, Sleeman K, Hall-Eidson P, Zeh C, Bhairavabhotla R, Zhang G, Adhikari A, Alemnji G, Cardo YR, Pinheiro A, Pocongo B, Eno LT, Shang JD, Ndongmo CB, Rosario H, Moreno O, De León LAC, Fonjungo P, Kabwe C, Ahuke-Mundeke S, Gama D, Dlamini S, Maphalala G, Abreha T, Purfield A, Gebrehiwot YT, Desalegn DM, Basiye F, Mwangi J, Bowen N, Mengistu Y, Lecher S, Kampira E, Kaba M, Bitilinyu-Bangoh J, Masamha G, Viegas SO, Beard RS, van Rooyen G, Shiningavamwe AN, I J M, Iriemenam NC, Mba N, Okoi C, Katoro J, Kenyi DL, Bior BK, Mwangi C, Nabadda S, Kaleebu P, Yingst SL, Chikwanda P, Veri L, Simbi R, Alexander H |
Jazyk: |
angličtina |
Zdroj: |
Emerging infectious diseases [Emerg Infect Dis] 2022 Dec; Vol. 28 (13), pp. S59-S68. |
DOI: |
10.3201/eid2813.220789 |
Abstrakt: |
The US President's Emergency Plan for AIDS Relief (PEPFAR) supports molecular HIV and tuberculosis diagnostic networks and information management systems in low- and middle-income countries. We describe how national programs leveraged these PEPFAR-supported laboratory resources for SARS-CoV-2 testing during the COVID-19 pandemic. We sent a spreadsheet template consisting of 46 indicators for assessing the use of PEPFAR-supported diagnostic networks for COVID-19 pandemic response activities during April 1, 2020, to March 31, 2021, to 27 PEPFAR-supported countries or regions. A total of 109 PEPFAR-supported centralized HIV viral load and early infant diagnosis laboratories and 138 decentralized HIV and TB sites reported performing SARS-CoV-2 testing in 16 countries. Together, these sites contributed to >3.4 million SARS-CoV-2 tests during the 1-year period. Our findings illustrate that PEPFAR-supported diagnostic networks provided a wide range of resources to respond to emergency COVID-19 diagnostic testing in 16 low- and middle-income countries. |
Databáze: |
MEDLINE |
Externí odkaz: |
|